Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$2.94MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Barry D. Quart
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 64
- Beta
- -0.22
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -15.08
Financials
Revenue
$2.94M-87.8%Net Income
$-36.68MEBITDA
$-36.89MFree Cash Flow
$-20.66MEPS (diluted)
$-0.61Shares Outstanding (diluted)
62.88M+12.7%Operating Expenses
$20.37MCash & Debt
$31.49MReturn of Capital
$0.00Revenue by Segment (annual)
$110.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $64.0K | $-55.48M | $-1.00 |
| 2024 | $26.03M | $-15.63M | $-0.28 |
| 2023 | $0.00 | $-62.11M | $-1.08 |
| 2022 | $0.00 | $-118.09M | $-14.50 |
| 2021 | $0.00 | $-202.27M | $-25.00 |
| 2020 | $0.00 | $-119.37M | $-14.45 |
| 2019 | $0.00 | $-24.46M | $-3.02 |
Valuation
CNTBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (2)
- Newsseekingalpha.com·6h ago·Positive
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
View source ↗ - Newsbenzinga.com·22h ago·Neutral
Why Is Connect Biopharma Stock Trading Lower on Tuesday? Connect Biopharma Holdings Limited (NASDAQ:CNTB) stock hit its 52-week low on Tuesday after releasing topline results from its global Phase 2 study evaluating rademikibart.
View source ↗
Earnings
Wed, Nov 11(in 8 weeks)
Consensus estimate $-0.27 per share
Typical surprise +14.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.27 vs $-0.31beat
- Tue, May 12$-0.34 vs $-0.29miss
- Tue, Mar 31$-0.27 vs $-0.30beat
- Wed, Nov 12$-0.04 vs $-0.03miss
- Wed, Aug 13$-0.03 vs $-0.22beat
- Thu, May 15$-0.03 vs $-0.26beat
Estimates and results for CNTB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CNTB officers and directors.
- Bought
- $4.4m
- Sold
- —
2 trades
0 trades
- Huang Jamesbought
- Huang Jamesbought
42 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CNTB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.